Literature DB >> 19708964

EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

S Evers1, J Afra, A Frese, P J Goadsby, M Linde, A May, P S Sándor.   

Abstract

BACKGROUND: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life.
OBJECTIVES: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel.
METHODS: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points. RECOMMENDATIONS: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708964     DOI: 10.1111/j.1468-1331.2009.02748.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  184 in total

Review 1.  Controversies in migraine: monotherapy.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  Treatment of perimenstrual migraine with triptans: an update.

Authors:  Barbara Casolla; Luana Lionetto; Serena Candela; Lidia D'Alonzo; Andrea Negro; Maurizio Simmaco; Paolo Martelletti
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 3.  Guideline for primary care management of headache in adults.

Authors:  Werner J Becker; Ted Findlay; Carmen Moga; N Ann Scott; Christa Harstall; Paul Taenzer
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

4.  Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.

Authors:  Georgia Tsaousi; Chryssa Pourzitaki; Spyridon Siafis; Athanassios Kyrgidis; Vasilios Grosomanidis; Dimitrios Kouvelas; Georgios Papazisis
Journal:  Eur J Clin Pharmacol       Date:  2019-11-25       Impact factor: 2.953

Review 5.  Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 6.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 7.  Mechanism of action of indomethacin in indomethacin-responsive headaches.

Authors:  Oliver Summ; Stefan Evers
Journal:  Curr Pain Headache Rep       Date:  2013-04

8.  Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women.

Authors:  Siri Amundsen; Torunn G Øvrebø; Netta Marie S Amble; Anne Christine Poole; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2016-09-13       Impact factor: 2.953

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 10.  Frovatriptan: a review of its use in the acute treatment of migraine.

Authors:  Mark Sanford
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.